Endo International Stock Price, News & Analysis (NASDAQ:ENDP)

$7.88 0.16 (2.07 %)
(As of 12/12/2017 04:00 PM ET)
Previous Close$7.72
Today's Range$7.60 - $7.92
52-Week Range$5.77 - $17.99
Volume5.48 million shs
Average Volume7.11 million shs
Market Capitalization$1.67 billion
P/E Ratio1.55
Dividend YieldN/A
Beta0.59

About Endo International (NASDAQ:ENDP)

Endo International logoEndo International PLC, formerly Endo Health Solutions Inc. is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel. The Company operates in three segments: Endo Pharmaceuticals, Qualitest and AMS. In June 2014, the Company's subsidiary, Endo Pharmaceuticals sold its pharmaceutical drug discovery platform to AsanaBioSciences, LLC. In June 2014, Asana BioSciences, LLC, an independent member of Amneal Alliance of Companies, acquired early-stage branded pharmaceutical discovery platform of Endo Pharmaceuticals, a subsidiary of Endo International plc. In June 2014, Trendlines Group acquired intellectual property developed within the framework of an R&D agreement with the Company. In July 2014, it acquired Grupo Farmaceutico Somar.

Receive ENDP News and Ratings via Email

Sign-up to receive the latest news and ratings for ENDP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Other
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ENDP
CUSIP29264F20
Phone011-353-1268-2000

Debt

Debt-to-Equity Ratio10.78%
Current Ratio1.08%
Quick Ratio0.86%

Price-To-Earnings

Trailing P/E Ratio1.55
Forward P/E Ratio2.15
P/E Growth2.04

Sales & Book Value

Annual Sales$4.01 billion
Price / Sales0.44
Cash Flow$9.73 per share
Price / Cash0.81
Book Value$12.12 per share
Price / Book0.65

Profitability

Trailing EPS($22.45)
Net Income$-3,347,060,000.00
Net Margins-126.97%
Return on Equity66.98%
Return on Assets8.38%

Miscellaneous

Employees4,894
Outstanding Shares223,310,000

Endo International (NASDAQ:ENDP) Frequently Asked Questions

What is Endo International's stock symbol?

Endo International trades on the NASDAQ under the ticker symbol "ENDP."

How were Endo International's earnings last quarter?

Endo International PLC (NASDAQ:ENDP) posted its earnings results on Thursday, November, 9th. The company reported $0.91 EPS for the quarter, beating the Zacks' consensus estimate of $0.85 by $0.06. The company had revenue of $786.90 million for the quarter, compared to the consensus estimate of $794.93 million. Endo International had a positive return on equity of 66.98% and a negative net margin of 126.97%. The company's revenue for the quarter was down 11.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.01 earnings per share. View Endo International's Earnings History.

When will Endo International make its next earnings announcement?

Endo International is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Endo International.

What guidance has Endo International issued on next quarter's earnings?

Endo International updated its FY17 earnings guidance on Thursday, November, 9th. The company provided earnings per share (EPS) guidance of $3.35-3.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.63. The company issued revenue guidance of $3.38-3.53 billion, compared to the consensus revenue estimate of $3.47 billion.

Where is Endo International's stock going? Where will Endo International's stock price be in 2017?

20 brokers have issued twelve-month target prices for Endo International's stock. Their forecasts range from $7.00 to $20.00. On average, they anticipate Endo International's share price to reach $11.59 in the next year. View Analyst Ratings for Endo International.

What are Wall Street analysts saying about Endo International stock?

Here are some recent quotes from research analysts about Endo International stock:

  • 1. Mizuho analysts commented, "We will update our rating and PT later. We summarize 3Q:17 performance in Exhibit 1." (11/10/2017)
  • 2. According to Zacks Investment Research, "Endo withdrew opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market following FDA’s request in June. The drug represented 4% of total 2016 revenues. Consequently, the company lowered its guidance. Headwinds in the form of declining generics base business and the legacy branded pain franchise remain a hangover. The generic business is under significant pressure due to intensifying consortium pricing pressures, and additional competitive entrants and product discontinuations as well as discrete factors, including destocking and shifts in purchase timing due to market conditions. Shares have significantly underperformed the industry in the last six months. Meanwhile, the company divested its non-core assets such as Belbuca and restructured its pain franchise to focus particularly on specialty branded business." (10/26/2017)
  • 3. JMP Securities analysts commented, "The FDA panel voted 8 yes, 18 no, and 1 abstain on whether Opana ER's benefits outweigh the risk. The FDA was concerned that the new Opana ER formulation just shifts the abuse route from nasal to injections. We do not view Opana ER as a growth driver and it is only 4% of our 2017 revenue estimate while declining 13% y/y. Our $20 price target includes an equal blend of PEG ratio and EV/EBITDA analysis of 1.3x and 8.5x, respectively, on our 2017 estimates." (3/15/2017)
  • 4. Royal Bank of Canada analysts commented, "Yesterday's AdComs' vote of 18 to 8 (one abstain) on OPANA ER's benefits no longer outweighing its risks will push a decision on the product's fate back to FDA. Whether it is removed or sees added restrictions we think it is likely we will see some downward P&L pressure but it is also worth noting that the stock was -25% in Mar ahead of the anticipated panel." (3/15/2017)

Are investors shorting Endo International?

Endo International saw a increase in short interest in November. As of November 15th, there was short interest totalling 23,486,012 shares, an increase of 19.5% from the October 31st total of 19,645,509 shares. Based on an average daily volume of 8,586,673 shares, the days-to-cover ratio is presently 2.7 days. Currently, 11.8% of the company's stock are short sold.

Who are some of Endo International's key competitors?

Who owns Endo International stock?

Endo International's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (1.01%), Diamond Hill Capital Management Inc. (0.32%), Ameriprise Financial Inc. (0.25%), California State Teachers Retirement System (0.17%), River & Mercantile Asset Management LLP (0.16%) and Van ECK Associates Corp (0.15%). Company insiders that own Endo International stock include Arthur J Higgins, Blaise Coleman, Matthew Joseph Maletta, Nancy J Hutson, Paul Campanelli, Roger H Kimmel, Silva Rajiv De, Terrance J Coughlin and William Spengler. View Institutional Ownership Trends for Endo International.

Who sold Endo International stock? Who is selling Endo International stock?

Endo International's stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Columbia Partners L L C Investment Management, California State Teachers Retirement System, Stoneridge Investment Partners LLC, HL Financial Services LLC, Municipal Employees Retirement System of Michigan, Aperio Group LLC and Ameriprise Financial Inc.. View Insider Buying and Selling for Endo International.

Who bought Endo International stock? Who is buying Endo International stock?

Endo International's stock was bought by a variety of institutional investors in the last quarter, including Diamond Hill Capital Management Inc., River & Mercantile Asset Management LLP, Van ECK Associates Corp, Cornerstone Capital Management Holdings LLC., Gamco Investors INC. ET AL, Crossmark Global Holdings Inc., Alps Advisors Inc. and LMR Partners LLP. Company insiders that have bought Endo International stock in the last two years include Arthur J Higgins, Blaise Coleman, Matthew Joseph Maletta, Paul Campanelli, Roger H Kimmel, Silva Rajiv De, Terrance J Coughlin and William Spengler. View Insider Buying and Selling for Endo International.

How do I buy Endo International stock?

Shares of Endo International can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Endo International's stock price today?

One share of Endo International stock can currently be purchased for approximately $7.88.

How big of a company is Endo International?

Endo International has a market capitalization of $1.67 billion and generates $4.01 billion in revenue each year. The company earns $-3,347,060,000.00 in net income (profit) each year or ($22.45) on an earnings per share basis. Endo International employs 4,894 workers across the globe.

How can I contact Endo International?

Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at 011-353-1268-2000 or via email at [email protected]


MarketBeat Community Rating for Endo International (ENDP)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  625 (Vote Outperform)
Underperform Votes:  585 (Vote Underperform)
Total Votes:  1,210
MarketBeat's community ratings are surveys of what our community members think about Endo International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Endo International (NASDAQ:ENDP) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.192.192.272.35
Ratings Breakdown: 1 Sell Rating(s)
15 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
15 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
16 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
13 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $13.39$13.58$19.00$23.63
Price Target Upside: 73.51% upside95.94% upside104.74% upside112.51% upside

Endo International (NASDAQ:ENDP) Consensus Price Target History

Price Target History for Endo International (NASDAQ:ENDP)

Endo International (NASDAQ:ENDP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/12/2017GuggenheimInitiated CoverageNeutral -> Neutral$8.50LowView Rating Details
11/10/2017Piper Jaffray CompaniesReiterated RatingHold$7.00N/AView Rating Details
11/10/2017MizuhoReiterated RatingBuyN/AView Rating Details
11/10/2017BMO Capital MarketsLower Price TargetMarket Perform$11.00 -> $10.00N/AView Rating Details
11/10/2017Cantor FitzgeraldLower Price TargetNeutral$9.00 -> $7.00N/AView Rating Details
11/10/2017CitigroupLower Price TargetNeutral$9.00 -> $7.00N/AView Rating Details
11/10/2017Royal Bank of CanadaLower Price TargetSector Perform -> Sector Perform$9.00 -> $8.00N/AView Rating Details
9/28/2017Goldman Sachs GroupInitiated CoverageSell -> Sell$7.00HighView Rating Details
8/14/2017Canaccord GenuitySet Price TargetHold$10.00HighView Rating Details
8/10/2017Morgan StanleyLower Price TargetEqual Weight$12.00 -> $8.00LowView Rating Details
8/10/2017CowenReiterated RatingHold$16.00HighView Rating Details
8/9/2017Deutsche BankSet Price TargetBuy$15.00 -> $13.00LowView Rating Details
8/8/2017OppenheimerReiterated RatingHoldHighView Rating Details
6/14/2017William BlairReiterated RatingMarket PerformLowView Rating Details
6/9/2017Stifel NicolausDowngradeBuy -> Hold$22.00 -> $15.00HighView Rating Details
3/20/2017Leerink SwannReiterated RatingMarket PerformLowView Rating Details
3/15/2017JMP SecuritiesReiterated RatingOutperform$20.00HighView Rating Details
2/6/2017BarclaysLower Price TargetEqual Weight$22.00 -> $15.00N/AView Rating Details
1/31/2017Susquehanna BancsharesUpgradeNeutral -> PositiveN/AView Rating Details
1/20/2017J P Morgan Chase & CoDowngradeOverweight -> Neutral$20.00N/AView Rating Details
9/29/2016Northland SecuritiesUpgradeMarket Perform -> Outperform$27.00N/AView Rating Details
4/2/2016NomuraReiterated RatingBuyN/AView Rating Details
(Data available from 12/12/2015 forward)

Earnings

Endo International (NASDAQ:ENDP) Earnings History and Estimates Chart

Earnings by Quarter for Endo International (NASDAQ:ENDP)

Endo International (NASDAQ ENDP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018$0.61N/AView Earnings Details
11/9/2017Q3$0.85$0.91$794.93 million$786.90 millionViewN/AView Earnings Details
8/8/20176/30/2017$0.74$0.93$832.66 million$875.73 millionViewListenView Earnings Details
5/9/2017Q1 17$1.10$1.23$1.02 billion$1.04 billionViewListenView Earnings Details
2/28/2017Q416$1.63$1.77$1.17 billion$1.24 billionViewListenView Earnings Details
11/8/2016Q316$0.81$1.01$862.47 million$894.30 millionViewListenView Earnings Details
8/8/2016Q216$0.74$0.86$873.50 million$921.00 millionViewListenView Earnings Details
5/5/2016Q116$1.04$1.08$960.96 million$963.54 millionViewListenView Earnings Details
2/29/2016Q415$1.27$1.36$1.07 billion$1.07 billionViewListenView Earnings Details
11/5/2015Q315$1.00$1.02$736.16 million$746.00 millionViewListenView Earnings Details
8/10/2015Q215$1.02$1.08$727.45 million$735.00 millionViewListenView Earnings Details
5/11/2015Q115$1.07$1.17$714.42 million$714.00 millionViewListenView Earnings Details
3/2/2015Q414$1.13$1.16$780.44 million$800.00 millionViewListenView Earnings Details
11/5/2014Q314$0.99$1.15$721.11 million$764.00 millionViewListenView Earnings Details
7/31/2014Q214$0.90$1.06$644.60 million$719.00 millionViewListenView Earnings Details
5/1/2014Q114$0.84$0.92$608.86 million$595.00 millionViewListenView Earnings Details
2/28/2014Q413$0.93$0.96$620.90 million$584.95 millionViewListenView Earnings Details
11/7/2013Q313$1.11$1.34$695.63 million$715.00 millionViewListenView Earnings Details
8/6/2013Q2 2013$1.15$1.42$721.01 million$766.51 millionViewListenView Earnings Details
5/7/2013Q1 2013$1.08$1.09$737.79 million$709.00 millionViewListenView Earnings Details
2/28/2013Q4 2012$1.54$1.62$807.98 million$801.06 millionViewListenView Earnings Details
11/5/2012Q312$1.26$1.28$788.53 million$750.50 millionViewN/AView Earnings Details
8/7/2012$1.19$1.27ViewN/AView Earnings Details
5/1/2012$0.86$0.87ViewN/AView Earnings Details
2/24/2012$1.32$1.40ViewN/AView Earnings Details
10/27/2011$1.28$1.25ViewN/AView Earnings Details
8/9/2011$1.06$1.05ViewN/AView Earnings Details
4/28/2011$1.00$1.00ViewN/AView Earnings Details
2/28/2011$0.97$1.06ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Endo International (NASDAQ:ENDP) Earnings Estimates

2017 EPS Consensus Estimate: $3.36
2018 EPS Consensus Estimate: $2.70
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$1.08$1.26$1.15
Q2 20173$0.75$0.80$0.77
Q3 20173$0.69$0.74$0.71
Q4 20173$0.64$0.84$0.73
Q1 20181$0.66$0.66$0.66
Q2 20181$0.66$0.66$0.66
Q3 20181$0.67$0.67$0.67
Q4 20181$0.71$0.71$0.71
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Endo International (NASDAQ:ENDP)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Endo International (NASDAQ ENDP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.50%
Institutional Ownership Percentage: 93.17%
Insider Trades by Quarter for Endo International (NASDAQ:ENDP)
Institutional Ownership by Quarter for Endo International (NASDAQ:ENDP)

Endo International (NASDAQ ENDP) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/15/2017Blaise ColemanCFOBuy6,500$7.89$51,285.00View SEC Filing  
8/15/2017Matthew Joseph MalettaEVPBuy3,000$8.02$24,060.00View SEC Filing  
8/14/2017Paul CampanelliCEOBuy6,500$7.71$50,115.00View SEC Filing  
8/10/2017Terrance J CoughlinCOOBuy20,000$7.70$154,000.00View SEC Filing  
3/16/2017Paul CampanelliCEOBuy2,300$10.72$24,656.00View SEC Filing  
3/9/2017Nancy J. HutsonDirectorSell5,325$10.82$57,616.50View SEC Filing  
11/15/2016Roger H. KimmelDirectorSell14,000$17.38$243,320.00View SEC Filing  
5/11/2016Arthur J HigginsDirectorBuy5,000$13.80$69,000.00View SEC Filing  
5/10/2016Arthur J HigginsDirectorBuy11,000$15.42$169,620.00View SEC Filing  
5/10/2016Paul CampanelliInsiderBuy13,000$15.53$201,890.00View SEC Filing  
3/17/2016William SpenglerDirectorBuy1,000$29.20$29,200.00View SEC Filing  
3/16/2016William SpenglerDirectorBuy1,000$35.24$35,240.00View SEC Filing  
3/14/2016Roger H KimmelDirectorBuy1,125$41.94$47,182.50View SEC Filing  
3/7/2016Matthew Joseph MalettaVPBuy500$44.48$22,240.00View SEC Filing  
3/7/2016Silva Rajiv DeCEOBuy2,250$44.50$100,125.00View SEC Filing  
3/1/2016Nancy J. HutsonDirectorSell3,413$42.19$143,994.47View SEC Filing  
11/12/2015Shane CookeDirectorBuy4,000$57.13$228,520.00View SEC Filing  
11/11/2015Michael HyattDirectorSell8,000$55.48$443,840.00View SEC Filing  
11/11/2015Paul CampanelliinsiderBuy2,100$55.69$116,949.00View SEC Filing  
11/11/2015Silva Rajiv DeCEOBuy9,006$55.52$500,013.12View SEC Filing  
11/11/2015Suketu UpadhyayCFOBuy4,450$56.37$250,846.50View SEC Filing  
11/11/2015Susan HallEVPBuy1,000$55.35$55,350.00View SEC Filing  
6/16/2015Arthur J HigginsDirectorBuy2,500$81.10$202,750.00View SEC Filing  
4/8/2015Caroline B ManogueVPSell105,562$91.90$9,701,147.80View SEC Filing  
11/14/2014Suketu UpadhyayCFOBuy3,700$66.94$247,678.00View SEC Filing  
8/5/2014Arthur J HigginsDirectorBuy3,500$65.65$229,775.00View SEC Filing  
6/9/2014John DeluccaDirectorSell6,764$68.83$465,566.12View SEC Filing  
5/29/2014Caroline B ManogueVPSell175,033$72.02$12,605,876.66View SEC Filing  
5/1/2014John DeluccaDirectorSell8,094$66.31$536,713.14View SEC Filing  
4/1/2014John DeluccaDirectorSell10,384$68.46$710,888.64View SEC Filing  
3/10/2014Arthur HigginsDirectorBuy5,000$73.00$365,000.00View SEC Filing  
3/10/2014Ivan GergelEVPSell75,637$72.47$5,481,413.39View SEC Filing  
8/26/2013Caroline ManogueVPSell145,592$39.40$5,736,324.80View SEC Filing  
8/8/2013Roger KimmelDirectorBuy5,478$36.50$199,947.00View SEC Filing  
4/9/2013Caroline B ManogueVPSell35,000$35.00$1,225,000.00View SEC Filing  
11/12/2012David HolveckCEOBuy7,425$26.84$199,287.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Endo International (NASDAQ ENDP) News Headlines

Source:
DateHeadline
Endo International (ENDP) Upgraded at BidaskClubEndo International (ENDP) Upgraded at BidaskClub
www.americanbankingnews.com - December 12 at 11:34 PM
Alexza Pharmaceuticals (ALXA) & Endo International (ENDP) Head-To-Head AnalysisAlexza Pharmaceuticals (ALXA) & Endo International (ENDP) Head-To-Head Analysis
www.americanbankingnews.com - December 12 at 1:40 PM
Analysts expect these large-cap US stocks to rise at least 25% in 2018 - Yahoo FinanceAnalysts expect these large-cap US stocks to rise at least 25% in 2018 - Yahoo Finance
finance.yahoo.com - December 12 at 10:00 AM
Guggenheim Starts Endo International plc (ENDP) at Neutral - StreetInsider.comGuggenheim Starts Endo International plc (ENDP) at Neutral - StreetInsider.com
www.streetinsider.com - December 12 at 10:00 AM
Comparing RegeneRx Biopharmaceuticals (RGRX) & Endo International (ENDP)Comparing RegeneRx Biopharmaceuticals (RGRX) & Endo International (ENDP)
www.americanbankingnews.com - December 11 at 11:24 PM
Endo International PLC (ENDP) Given Consensus Rating of "Hold" by BrokeragesEndo International PLC (ENDP) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - December 11 at 6:46 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Endo International plc (ENDP) and Lead Plaintiff Deadline - January 16, 2018SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Endo International plc (ENDP) and Lead Plaintiff Deadline - January 16, 2018
finance.yahoo.com - December 11 at 5:28 PM
Critical Analysis: RegeneRx Biopharmaceuticals (RGRX) versus Endo International (ENDP)Critical Analysis: RegeneRx Biopharmaceuticals (RGRX) versus Endo International (ENDP)
www.americanbankingnews.com - December 11 at 3:34 PM
Head-To-Head Comparison: RegeneRx Biopharmaceuticals (RGRX) versus Endo International (ENDP)Head-To-Head Comparison: RegeneRx Biopharmaceuticals (RGRX) versus Endo International (ENDP)
www.americanbankingnews.com - December 9 at 1:18 PM
Head-To-Head Contrast: Alexza Pharmaceuticals (ALXA) versus Endo International (ENDP)Head-To-Head Contrast: Alexza Pharmaceuticals (ALXA) versus Endo International (ENDP)
www.americanbankingnews.com - December 9 at 8:04 AM
Endo International Plc breached its 50 day moving average in a Bullish Manner : ENDP-US : December 8, 2017Endo International Plc breached its 50 day moving average in a Bullish Manner : ENDP-US : December 8, 2017
finance.yahoo.com - December 8 at 9:33 AM
Financial Review: Endo International (ENDP) vs. RegeneRx Biopharmaceuticals (RGRX)Financial Review: Endo International (ENDP) vs. RegeneRx Biopharmaceuticals (RGRX)
www.americanbankingnews.com - December 8 at 1:30 AM
Endo International (ENDP) versus RegeneRx Biopharmaceuticals (RGRX) Financial AnalysisEndo International (ENDP) versus RegeneRx Biopharmaceuticals (RGRX) Financial Analysis
www.americanbankingnews.com - December 7 at 9:38 PM
Robbins Arroyo LLP: Endo International plc (ENDP) Misled Shareholders According to a Recently Filed Class ActionRobbins Arroyo LLP: Endo International plc (ENDP) Misled Shareholders According to a Recently Filed Class Action
finance.yahoo.com - December 6 at 9:45 AM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Endo International plc (ENDP) and Lead Plaintiff Deadline: January 16, 2018SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Endo International plc (ENDP) and Lead Plaintiff Deadline: January 16, 2018
finance.yahoo.com - December 5 at 5:12 PM
Reviewing Endo International (ENDP) & RegeneRx Biopharmaceuticals (RGRX)Reviewing Endo International (ENDP) & RegeneRx Biopharmaceuticals (RGRX)
www.americanbankingnews.com - December 5 at 5:28 AM
Financial Survey: Alexza Pharmaceuticals (ALXA) vs. Endo International (ENDP)Financial Survey: Alexza Pharmaceuticals (ALXA) vs. Endo International (ENDP)
www.americanbankingnews.com - December 4 at 5:12 PM
Reviewing Endo International (ENDP) and RegeneRx Biopharmaceuticals (RGRX)Reviewing Endo International (ENDP) and RegeneRx Biopharmaceuticals (RGRX)
www.americanbankingnews.com - December 3 at 4:14 PM
Analyzing Endo International (ENDP) & RegeneRx Biopharmaceuticals (RGRX)Analyzing Endo International (ENDP) & RegeneRx Biopharmaceuticals (RGRX)
www.americanbankingnews.com - December 2 at 9:36 PM
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Endo International plc of Class Action Lawsuit and Upcoming Deadline – ENDPSHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Endo International plc of Class Action Lawsuit and Upcoming Deadline – ENDP
finance.yahoo.com - December 2 at 9:45 AM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Endo International plc (ENDP) and Lead Plaintiff Deadline: January 16, 2018SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Endo International plc (ENDP) and Lead Plaintiff Deadline: January 16, 2018
finance.yahoo.com - December 1 at 4:55 PM
 Analysts Expect Endo International PLC (ENDP) Will Announce Quarterly Sales of $761.32 Million Analysts Expect Endo International PLC (ENDP) Will Announce Quarterly Sales of $761.32 Million
www.americanbankingnews.com - November 30 at 4:38 AM
Endo Luxembourg Finance I Company S.a.r.l. -- Moodys revises Endos outlook to negative from stable; affirms ratingsEndo Luxembourg Finance I Company S.a.r.l. -- Moody's revises Endo's outlook to negative from stable; affirms ratings
finance.yahoo.com - November 29 at 5:35 PM
RegeneRx Biopharmaceuticals (RGRX) & Endo International (ENDP) Head to Head AnalysisRegeneRx Biopharmaceuticals (RGRX) & Endo International (ENDP) Head to Head Analysis
www.americanbankingnews.com - November 28 at 9:32 PM
Endo International PLC (ENDP) Sees Large Growth in Short InterestEndo International PLC (ENDP) Sees Large Growth in Short Interest
www.americanbankingnews.com - November 27 at 11:32 PM
Head-To-Head Review: Endo International (ENDP) & Alexza Pharmaceuticals (ALXA)Head-To-Head Review: Endo International (ENDP) & Alexza Pharmaceuticals (ALXA)
www.americanbankingnews.com - November 27 at 3:56 PM
Endo International Plc breached its 50 day moving average in a Bearish Manner : ENDP-US : November 27, 2017Endo International Plc breached its 50 day moving average in a Bearish Manner : ENDP-US : November 27, 2017
finance.yahoo.com - November 27 at 3:45 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Endo International plc of Class Action Lawsuit and Upcoming Deadline - ENDPSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Endo International plc of Class Action Lawsuit and Upcoming Deadline - ENDP
finance.yahoo.com - November 25 at 6:18 PM
RegeneRx Biopharmaceuticals (RGRX) versus Endo International PLC (ENDP) Financial ReviewRegeneRx Biopharmaceuticals (RGRX) versus Endo International PLC (ENDP) Financial Review
www.americanbankingnews.com - November 25 at 5:12 AM
Contrasting RegeneRx Biopharmaceuticals (RGRX) and Endo International PLC (ENDP)Contrasting RegeneRx Biopharmaceuticals (RGRX) and Endo International PLC (ENDP)
www.americanbankingnews.com - November 24 at 7:20 PM
Analyzing RegeneRx Biopharmaceuticals (RGRX) & Endo International PLC (ENDP)Analyzing RegeneRx Biopharmaceuticals (RGRX) & Endo International PLC (ENDP)
www.americanbankingnews.com - November 24 at 11:40 AM
RegeneRx Biopharmaceuticals (RGRX) vs. Endo International PLC (ENDP) Financial SurveyRegeneRx Biopharmaceuticals (RGRX) vs. Endo International PLC (ENDP) Financial Survey
www.americanbankingnews.com - November 24 at 1:24 AM
Interesting ENDP Put And Call Options For January 2018Interesting ENDP Put And Call Options For January 2018
www.nasdaq.com - November 22 at 7:04 PM
Interesting ENDP Put And Call Options For July 2018Interesting ENDP Put And Call Options For July 2018
www.thestreet.com - November 21 at 6:30 PM
Critical Review: Endo International PLC (ENDP) versus Alexza Pharmaceuticals (ALXA)Critical Review: Endo International PLC (ENDP) versus Alexza Pharmaceuticals (ALXA)
www.americanbankingnews.com - November 21 at 1:22 AM
Endo International PLC (ENDP) and Alexza Pharmaceuticals (ALXA) Head to Head AnalysisEndo International PLC (ENDP) and Alexza Pharmaceuticals (ALXA) Head to Head Analysis
www.americanbankingnews.com - November 19 at 1:38 AM
Endo to Participate at Bank of America Merrill Lynch Leveraged Finance ConferenceEndo to Participate at Bank of America Merrill Lynch Leveraged Finance Conference
finance.yahoo.com - November 17 at 5:04 PM
Inside Endo’s Key Business SegmentsInside Endo’s Key Business Segments
finance.yahoo.com - November 17 at 12:34 PM
Inside Endo’s Branded Pharma and International SegmentsInside Endo’s Branded Pharma and International Segments
finance.yahoo.com - November 17 at 12:34 PM
Inside Endo’s Measures to Boost MarginsInside Endo’s Measures to Boost Margins
finance.yahoo.com - November 17 at 12:34 PM
ENDO INTERNATIONAL INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing in Endo International, Plc to Contact the FirmENDO INTERNATIONAL INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing in Endo International, Plc to Contact the Firm
finance.yahoo.com - November 16 at 6:55 PM
Endo unit cleared of liability in first testosterone replacement trialEndo unit cleared of liability in first testosterone replacement trial
finance.yahoo.com - November 16 at 6:55 PM
Endo on the Street: Analyst Recommendations in NovemberEndo on the Street: Analyst Recommendations in November
finance.yahoo.com - November 16 at 6:55 PM
Endo International PLC (ENDP) Receives Average Recommendation of "Hold" from AnalystsEndo International PLC (ENDP) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 16 at 4:16 PM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Endo ... - PR Newswire (press release)SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Endo ... - PR Newswire (press release)
www.prnewswire.com - November 16 at 1:53 PM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Endo International plc (ENDP) and Lead Plaintiff Deadline: January 16, 2018SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Endo International plc (ENDP) and Lead Plaintiff Deadline: January 16, 2018
finance.yahoo.com - November 16 at 1:53 PM
Alexza Pharmaceuticals (ALXA) and Endo International PLC (ENDP) Critical ReviewAlexza Pharmaceuticals (ALXA) and Endo International PLC (ENDP) Critical Review
www.americanbankingnews.com - November 16 at 8:37 AM
Research Analysts Offer Predictions for Endo International PLCs FY2017 Earnings (ENDP)Research Analysts Offer Predictions for Endo International PLC's FY2017 Earnings (ENDP)
www.americanbankingnews.com - November 15 at 6:56 AM
Brokers Issue Forecasts for Endo International PLCs FY2018 Earnings (ENDP)Brokers Issue Forecasts for Endo International PLC's FY2018 Earnings (ENDP)
www.americanbankingnews.com - November 13 at 8:58 AM
Endo International PLC (ENDP) Price Target Cut to $8.00Endo International PLC (ENDP) Price Target Cut to $8.00
www.americanbankingnews.com - November 12 at 1:10 PM

SEC Filings

Endo International (NASDAQ:ENDP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Endo International (NASDAQ:ENDP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Endo International (NASDAQ ENDP) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.